Cartherics CEO Alan Trounson ranked among the world’s most prominent scientists
Posted: 4 April 2022 The respected scientific platform Research.com has published the 2022 Edition of its Ranking of Top 1000 Scientists in the area of Biology and Biochemistry. BioMelbourne Network Member Cartherics welcomes the findings. In a notice…
2023 Australian Academy of Science Awards nominations closing soon
Posted: 4 April 2022 Nominations closing: 1 May 2022 Each year, the Australian Academy of Science shines a light on researchers who have made outstanding contributions to science, and in progressing the advancement of science in Australia, by…
Research Australia’s response to the Federal Budget
Posted: 31 March 2021 See below for BioMelbourne Network Member Research Australia’s response to the 2022/23 Federal Budget. The rising cost of living has become a key election issue and this Budget delivers cash payments, extends tax relief…
LaunchVic CEO wins Global Entrepreneurship Network Compass Award
Posted: 30 March 2022 BioMelbourne Network would like to congratulate LaunchVic CEO, Dr Kate Cornick, who has won the Global Entrepreneurship Network Compass Award. From LaunchVic We are incredibly proud of our CEO, Dr Kate Cornick who has…
AusBiotech’s AusBioNSW launched
Posted: 29 March 2022 AusBiotech is proud to launch AusBioNSW, a new peak industry membership body for NSW, to represent, connect, and promote NSW organisations doing business in and with the local, national and global life sciences economy.…
Almac Group support Agios’ road to FDA approval
Posted: 24 March 2022 BioMelbourne Network Member Almac Group is proud to confirm it has supported Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, in the clinical trial and rapid…
Neuren receives FDA approval
Posted: 23 March 2022 BioMelbourne Network Member, Neuren Pharmaceuticals, has received approval from the US Food and Drug Administration (FDA) to proceed with the Phase 2 trial of NNZ-2591 in PhelanMcDermid syndrome (PMS). The Investigational New Drug application…
Technovalia, Sypharma and BioNet announce Australian Vaccine Hub
Posted: 23 March 2022 Technovalia, Sypharma and BioNet announce the establishment of Genetis, the first Australian Vaccine Development and Manufacturing Hub for mRNA, DNA and recombinant vaccines. Establishment of the first end-to-end Australian capability for product development and…
New national agency to advance genomic medicine welcomed
Posted: 22 March 2022 Australian Genomics Lead Professor Kathryn North says a new national agency to support genomic medicine will help propel the integration of genomics into mainstream healthcare, a transformative approach to patient diagnosis and treatment. She…
World’s first lung scanner to change millions of lives
Posted: 22 March 2022 Australians with lung conditions will be able to access the world’s first and only dedicated lung scanner, which was developed in Australia by BioMelbourne Network Member 4DMedical. Funded through the Morrison Government’s landmark Medical…
Imagion Biosystems: Breast cancer first-in-human study update
Posted: 18 March 2022 Imagion Biosystems Limited, a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide this update on the progress of its first-in-human study for the MagSense HER2 breast cancer…
PRAXIS: Quality Management in Research Virtual Workshop
Posted: 15 March 2022 Learn how to improve your unit processes, minimise delays, and increase the quality of your research by enrolling into PRAXIS Australia’s Quality by Design virtual workshop. On completion, you will be able to: Explain…
